The Technical Analyst
TRACON Pharmaceuticals [TCON]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
TRACON Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
5.08% $1.913
America/New_York / 23 apr 2024 @ 10:11
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 87.03 mill |
| EPS: | -0.110 |
| P/E: | -17.39 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 45.50 mill |
| Avg Daily Volume: | 0.238 mill |
| RATING 2024-04-22 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Buy | |
| DE: | Strong Sell | |
| P/E: | Buy | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -17.39 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.96x |
| Company: PE -17.39 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.554 (-71.02%) $-1.358 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.324 - 3.50 ( +/- 83.08%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-12 | Brown Scott B. | Buy | 224 800 | Employee Stock Option (Right to Buy) |
| 2023-04-20 | Brown Scott B. | Buy | 3 500 | Common Stock |
| 2024-03-12 | Theuer Charles | Buy | 518 300 | Employee Stock Option (Right to Buy) |
| 2023-10-20 | Theuer Charles | Buy | 3 500 | Common Stock |
| 2023-04-20 | Theuer Charles | Buy | 3 500 | Common Stock |
| INSIDER POWER |
|---|
| 80.83 |
| Last 100 transactions |
| Buy: 3 843 498 | Sell: 406 947 |
Forecast:
11:50 - $1.845
Live Trading Signals (every 1 min)
Forecast
1: 10:20 - $1.925
Forecast 2: 11:10 - $1.873
Forecast 3: 11:50 - $1.845
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.913 (5.08% ) |
| Volume | 0.0074 mill |
| Avg. Vol. | 0.238 mill |
| % of Avg. Vol | 3.09 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TCON
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:23 | sell | $0.194 | N/A | Active |
|---|
TCON
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
Latest Press Releases
2024-04-08 09:10:00 - Press Release
Tracon Pharmaceuticals Announces Reverse Stock Split
San diego, april 08, 2024 (globe newswire) -- tracon pharmaceuticals (nasdaq: tcon), a clinical stage biopharmaceutical company utilizing a cost-efficient, cro-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced that, following stockholder approval at the special meeting of stockholders held on september 6, 2023 of a proposal authorizing the board of directors of the company (the board) to amend the company's amended and restated certificate of incorporation to effect a reverse stock split of the company's outstanding common stock at a ratio in the range of one-for-five to one-for-twenty, the company's board today approved a reverse stock split of the company's common stock at a ratio of one-for-twenty.
2024-03-05 16:02:00 - Press Release
Tracon Pharmaceuticals Reports Fourth Quarter And Year-end 2023 Financial Results And Provides Corporate Update
San diego, march 05, 2024 (globe newswire) -- tracon pharmaceuticals, inc. (nasdaq: tcon), a clinical stage biopharmaceutical company utilizing a cost-efficient, cro-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the fourth quarter and year ended december 31, 2023. the company will host a conference call and webcast today at 4:30 pm eastern time / 1:30 pm pacific time.
2024-02-28 16:02:00 - Press Release
Tracon To Report Fourth Quarter And Year-end 2023 Financial Results And Provide Corporate Update On March 5, 2024
San diego, feb. 28, 2024 (globe newswire) -- tracon pharmaceuticals, inc. (nasdaq: tcon), a clinical stage biopharmaceutical company utilizing a cost-efficient, cro-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its fourth quarter and year-end 2023 financial and operating results after the close of u.s. financial markets on tuesday, march 5, 2024. in addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
2023-12-20 08:00:00 - Press Release
Tracon Pharmaceuticals Provides Positive Update On Ongoing Envasarc Pivotal Phase 2 Trial
Objective response rate by investigator review increased to 15% since interim analysis in september full envasarc enrollment expected in 1q 2024 and final data anticipated during 3q 2024 san diego, dec. 20, 2023 (globe newswire) -- tracon pharmaceuticals (nasdaq: tcon), a clinical stage biopharmaceutical company utilizing a cost-efficient, cro-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced that the ongoing pivotal phase 2 envasarc trial has enrolled more than 70 of the 80 planned patients in cohort c of single agent envafolimab treatment at a dose of 600 mg subq every three weeks...
2023-11-20 08:00:00 - Press Release
Tracon Pharmaceuticals Announces License Of Product Development Platform For $3.0 Million Upfront Payment
San diego, nov. 20, 2023 (globe newswire) -- tracon pharmaceuticals, inc. (nasdaq: tcon), a clinical stage biopharmaceutical company utilizing a cost-efficient, cro-independent product development platform (pdp) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced it has licensed its proprietary pdp of cro-independent clinical research to a clinical stage biotech company for a $3.0 million upfront payment.
Latest News
2024-04-10 06:30:00 - InvestorPlace
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024
Now could be a great time for investors to consider stacking up on penny stocks. These companies often have significant growth potential.
2024-02-28 16:02:00 - GlobeNewsWire
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its fourth quarter and year-end 2023 financial and operating results after the close of U.S. financial markets on Tuesday, March 5, 2024. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
2023-11-21 07:55:28 - InvestorPlace
Why Is Tracon Pharmaceuticals (TCON) Stock Up 19% Today?
Tracon Pharmaceuticals (NASDAQ: TCON ) stock is rocketing higher on Tuesday as investors react to a licensing agreement for its product development platform ( PDP ). According to a press release from the company, it has licensed this to a clinical-stage biotech company for an upfront payment of $3 million.
2023-11-13 09:29:25 - InvestorPlace
Why Is Tracon Pharmaceuticals (TCON) Stock Down 22% Today?
Tracon Pharmaceuticals (NASDAQ: TCON ) stock is falling on Monday as the company's shares retreat from a massive rally on Friday. That rally saw shares of TCON stock climb 43.9% higher during normal trading hours.
2023-11-10 07:45:10 - InvestorPlace
Why Is Tracon Pharmaceuticals (TCON) Stock Up 130% Today?
Tracon Pharmaceuticals (NASDAQ: TCON ) stock is rocketing higher on Friday after the biopharmaceutical company announced results for the third quarter of 2023. Tracon Pharmaceuticals starts its report with adjusted earnings per share of 29 cents.
2023-11-09 21:10:07 - Seeking Alpha
TRACON Pharmaceuticals, Inc. (TCON) Q3 2023 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET Company Participants Dr. Charles Theuer - President and CEO Scott Brown - CFO Conference Call Participants Ed White - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Third Quarter 2023 Earnings Conference Call.
2023-09-05 16:02:00 - GlobeNewsWire
TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate at the following upcoming investor conferences and provide a company overview:
2023-08-25 07:20:36 - InvestorPlace
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole
Investing in biotech stocks can be challenging. The rewards can be great when your company hits on a popular drug, treatment or product.
2023-08-14 18:50:18 - Seeking Alpha
TRACON Pharmaceuticals, Inc. (TCON) Q2 2023 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q2 2023 Earnings Call August 14, 2023 4:30 PM ET Company Participants Charles P. Theuer - President and CEO Scott B.
2023-08-03 10:48:49 - PennyStocks
Penny Stocks To Buy Now? 3 With Ratings Up To 1,742%
In a stock market characterized by growing unpredictability, traders are leaning on every possible resource. One such indispensable tool, whether dealing with penny stocks or more expensive shares, is the insight provided by analysts.